Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.410
-0.090 (-2.57%)
At close: Jun 26, 2026, 4:00 PM EDT
3.395
-0.015 (-0.44%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
The company also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.
Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Inventiva S.A.
| Country | France |
| Founded | 2011 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Andrew Obenshain |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | IVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.40 |
| CIK Code | 0001756594 |
| CUSIP Number | 46124U107 |
| ISIN Number | US46124U1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew Obenshain | Chief Executive Officer |
| Dr. Pierre Broqua Ph.D. | Co-Founder |
| Jean Volatier | Executive Vice President Finance and Corporate Social Responsibility |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs and Quality Assurance and Head of Regulatory Affairs |
| Jason A. Campagna M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Axel-Sven Malkomes | Chief Financial Officer |
| Susan Coles | Chief Legal Officer |
| Pamela Herbster | Chief People Officer |
| Pascaline Clerc Ph.D. | Executive Vice President of External and Corporate Affairs |
| Nazira Amra M.D. | Chief Commercial Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 6-K | Report of foreign issuer |
| Jun 12, 2026 | 6-K | Report of foreign issuer |
| Jun 9, 2026 | 6-K | Report of foreign issuer |
| Jun 3, 2026 | 6-K | Report of foreign issuer |
| Jun 3, 2026 | 6-K | Report of foreign issuer |
| Jun 2, 2026 | 424B5 | Filing |
| Jun 2, 2026 | FWP | Free Writing Prospectus |
| Jun 2, 2026 | F-3ASR | Filing |
| May 26, 2026 | 6-K | Report of foreign issuer |
| May 22, 2026 | 6-K | Report of foreign issuer |